India’s Ranbaxy Gets Approval To Market Dementia Drug In Canada

MUMBAI – Ranbaxy PharmaceuticalsCanada Inc (RPCI),a wholly-owned subsidiary of India’sRanbaxy, announced that ithas received approval in Decemberto manufacture and marketRAN-Donepezil Hydrochloride5 mg and 10 mg tablets fromHealth Canada.The total market size ofAricept (Donepezil Hydrochloride)in Canada is $153.9 million($CAD). Donepezil Hydrochlorideis indicated in the treatmentof dementia in Alzheimer’s patients.“We are pleased to havegained approval for DonepezilHydrochloride from Health Canadaand are proud to announcea day one launch. The finisheddosage form will be manufacturedat Ohm Laboratories locatedin New Jersey, USA, andRanbaxy anticipates this launchwill be beneficial to patients andhealthcare professionals, as wellas a positive economic benefitto the healthcare system of Canada,”said Paul Drake, PresidentRPCI, in a company statement.